Tuberculin skin test reversion following isoniazid preventive therapy reflects diversity of immune response to primary Mycobacterium tuberculosis infection

PLoS ONE

Volumn 9, Issue 5, 2014, Pages

  Johnson, Denise F ^a   Malone, LaShaunda L ^a   Zalwango, Sarah ^a   Oketcho, Joy Mukisa ^a   Chervenak, Keith A ^a   Thiel, Bonnie ^a   Mayanja Kizza, Harriet ^a,b   Stein, Catherine M ^c   Boom, W Henry ^a   Lancioni, Christina L ^d  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b MAKERERE UNIVERSITY COLLEGE OF HEALTH SCIENCES   (Uganda)

^c CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; ISONIAZID; MYCOBACTERIUM ANTIGEN; TUBERCULOSTATIC AGENT;

ADOLESCENT; ADULT; ARTICLE; BACTERIAL TRANSMISSION; CHILD; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; DEMOGRAPHY; FEMALE; HUMAN; HUMAN EXPERIMENT; IMMUNE RESPONSE; MICROBIAL IMMUNITY; MIDDLE AGED; NONHUMAN; NORMAL HUMAN; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; TREATMENT DURATION; TUBERCULIN TEST; TUBERCULIN TEST REVERSION; TUBERCULOSIS; UGANDA; YOUNG ADULT; DRUG EFFECTS; IMMUNE SYSTEM; LATENT TUBERCULOSIS; MALE; METABOLISM; MICROBIOLOGY; MYCOBACTERIUM TUBERCULOSIS; PHENOTYPE; PRESCHOOL CHILD;

ADOLESCENT; ADULT; ANTITUBERCULAR AGENTS; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; IMMUNE SYSTEM; INTERFERON-GAMMA; ISONIAZID; LATENT TUBERCULOSIS; MALE; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; PHENOTYPE; PROSPECTIVE STUDIES; TUBERCULIN TEST; TUBERCULOSIS; UGANDA; YOUNG ADULT;

EID: 84900435568     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0096613     Document Type: Article

References (37)

1. World Health Organization (2013) Global Tuberculosis Report 2013. WHO/HTM/TB/201315.
2. Tufariello JM, Chan J, Flynn JL (2003) Latent tuberculosis: mechanisms of host and bacillus that contribute to persistent infection. Lancet Infect Dis 3: 578-590. (Pubitemid 37064537)
3. Enarson DA, Rouillon A. (1998) The epidemiologic basis of tuberculosis control. In: Davies P, editor. Clinical Tuberculosis. London: Chapman & Hall Medical. pp. 35-52.
4. Mack U, Migliori GB, Sester M, Rieder HL, Ehlers S, et al. (2009) LTBI: latent tuberculosis infection or lasting immune responses to M. tuberculosis? A TBNET consensus statement. Eur Respir J 33: 956-973.
5. Fine PE, Bruce J, Ponnighaus JM, Nkhosa P, Harawa A, et al. (1999) Tuberculin sensitivity: conversions and reversions in a rural African population. Int J Tuberc Lung Dis 3: 962-975.
6. Friedman LN, Nash ER, Bryant J, Henry S, Shi J, et al. (2006) High rate of negative results of tuberculin and QuantiFERON tests among individuals with a history of positive skin test results. Infect Control Hosp Epidemiol 27: 436-441. (Pubitemid 43835523)
7. Felten MK, van der Merwe CA (1989) Random variation in tuberculin sensitivity in schoolchildren. Serial skin testing before and after preventive treatment for tuberculosis. Am Rev Respir Dis 140: 1001-1006. (Pubitemid 19259503)
8. Perez-Stable EJ, Flaherty D, Schecter G, Slutkin G, Hopewell PC (1988) Conversion and reversion of tuberculin reactions in nursing home residents. Am Rev Respir Dis 137: 801-804. (Pubitemid 18099288)
9. Ferebee SH (1970) Controlled chemoprophylaxis trials in tuberculosis. A general review. Bibl Tuberc 26: 28-106.
10. Pai M, Joshi R, Dogra S, Mendiratta DK, Narang P, et al. (2006) Serial testing of health care workers for tuberculosis using interferon-gamma assay. Am J Respir Crit Care Med 174: 349-355. (Pubitemid 44156616)
11. Pai M, Joshi R, Dogra S, Mendiratta DK, Narang P, et al. (2006) Persistently elevated T cell interferon-gamma responses after treatment for latent tuberculosis infection among health care workers in India: a preliminary report. J Occup Med Toxicol 1: 7.
12. Wilkinson KA, Kon OM, Newton SM, Meintjes G, Davidson RN, et al. (2006) Effect of treatment of latent tuberculosis infection on the T cell response to Mycobacterium tuberculosis antigens. J Infect Dis 193: 354-359. (Pubitemid 43122334)
13. Guwatudde D, Nakakeeto M, Jones-Lopez EC, Maganda A, Chiunda A, et al. (2003) Tuberculosis in household contacts of infectious cases in Kampala, Uganda. Am J Epidemiol 158: 887-898. (Pubitemid 37323251)
14. Guwatudde D, Zalwango S, Kamya MR, Debanne SM, Diaz MI, et al. (2003) Burden of tuberculosis in Kampala, Uganda. Bull World Health Organ 81: 799-805. (Pubitemid 37541470)
15. Mahan CS, Zalwango S, Thiel BA, Malone LL, Chervenak KA, et al. (2012) Innate and adaptive immune responses during acute M. tuberculosis infection in adult household contacts in Kampala, Uganda. Am J Trop Med Hyg 86: 690-697.
16. Whalen CC, Chiunda A, Zalwango S, Nshuti L, Jones-Lopez E, et al. (2006) Immune correlates of acute Mycobacterium tuberculosis infection in household contacts in Kampala, Uganda. Am J Trop Med Hyg 75: 55-61. (Pubitemid 351627571)
17. Chiunda A (2012) Impact of Geographic Distance on TB Control in Kampala, Uganda. Cleveland: Case Western Reserve University. 104 p.
18. American Thoracic Society (2000) Targeted tuberculin testing and treatment of latent tuberculosis infection. MMWR Recomm Rep 49: 1-51.
19. American Thoracic Society (1981) Diagnostic Standards and classifcation of tuberculosis and other mycobcaterial diseases. Am Rev Respir Dis 123: 1-16.
20. Menzies D (1999) Interpretation of repeated tuberculin tests. Boosting, conversion, and reversion. Am J Respir Crit Care Med 159: 15-21.
21. Marais BJ, Gie RP, Schaaf HS, Hesseling AC, Obihara CC, et al. (2004) The clinical epidemiology of childhood pulmonary tuberculosis: a critical review of literature from the pre-chemotherapy era. Int J Tuberc Lung Dis 8: 278-285. (Pubitemid 38624864)
22. Mandalakas AM, van Wyk S, Kirchner HL, Walzl G, Cotton M, et al. (2013) Detecting tuberculosis infection in HIV-infected children: a study of diagnostic accuracy, confounding and interaction. Pediatr Infect Dis J 32: e111-118.
23. Dahlstrom AW, Wilson JL, Sedlacek BB (1960) The immediate effectiveness of isoniazid chemoprophylaxis as determined by the tuberculin test. A five-year study including 5,555 Navajo and Pueblo children from birth to 15 years of age and the use of isonicotinic acid hydrazide in the prevention of tuberculosis. Dis Chest 38: 599-603.
24. Daniel TM, Bowerfind ES, Jr. (1967) Reversion of recently acquired tuberculin reactivity during isoniazid prophylaxis. Am Rev Respir Dis 95: 500-502.
25. Houk VN, Kent DC, Sorensen K, Baker JH (1968) The eradication of tuberculosis infection by isoniazid chemoprophylaxis. Arch Environ Health 16: 46-50.
26. Atuk NO, Hunt EH (1971) Serial tuberculin testing and isoniazid therapy in general hospital employees. JAMA 218: 1795-1798.
27. Arneil AS, McMichael B (1974) Effect of INH reversion rates of (very) recent converters. Can J Public Health 65: 197.
28. Adams JM, Kalajan VA, Mork BO, Rosenblatt M, Rothrock WJ, et al. (1959) Reversal of tuberculin reaction in early tuberculosis. Dis Chest 35: 348-356.
29. Cauthen GM, Snider DE, Jr., Onorato IM (1994) Boosting of tuberculin sensitivity among Southeast Asian refugees. Am J Respir Crit Care Med 149: 1597-1600. (Pubitemid 24175981)
30. Huebner RE, Schein MF, Bass JB, Jr. (1993) The tuberculin skin test. Clin Infect Dis 17: 968-975. (Pubitemid 23358739)
31. Lee SW, Oh DK, Lee SH, Kang HY, Lee CT, et al. (2011) Time interval to conversion of interferon-gamma release assay after exposure to tuberculosis. Eur Respir J 37: 1447-1452.
32. Goletti D, Parracino MP, Butera O, Bizzoni F, Casetti R, et al. (2007) Isoniazid prophylaxis differently modulates T-cell responses to RD1-epitopes in contacts recently exposed to Mycobacterium tuberculosis: a pilot study. Respir Res 8: 5.
33. Chee CB, KhinMar KW, Gan SH, Barkham TM, Pushparani M, et al. (2007) Latent tuberculosis infection treatment and T-cell responses to Mycobacterium tuberculosis-specific antigens. Am J Respir Crit Care Med 175: 282-287.
34. Ewer K, Millington KA, Deeks JJ, Alvarez L, Bryant G, et al. (2006) Dynamic antigen-specific T-cell responses after point-source exposure to Mycobacterium tuberculosis. Am J Respir Crit Care Med 174: 831-839. (Pubitemid 44511666)
35. Hill PC, Brookes RH, Fox A, Jackson-Sillah D, Jeffries DJ, et al. (2007) Longitudinal assessment of an ELISPOT test for Mycobacterium tuberculosis infection. PLoS Med 4: e192.
36. Demissie A, Leyten EM, Abebe M, Wassie L, Aseffa A, et al. (2006) Recognition of stage-specific mycobacterial antigens differentiates between acute and latent infections with Mycobacterium tuberculosis. Clin Vaccine Immunol 13: 179-186. (Pubitemid 43383784)
37. Arend SM, Andersen P, van Meijgaarden KE, Skjot RL, Subronto YW, et al. (2000) Detection of active tuberculosis infection by T cell responses to earlysecreted antigenic target 6-kDa protein and culture filtrate protein 10. J Infect Dis 181: 1850-1854. (Pubitemid 30387793)